Business
New To The Street / Newsmax TV Announces 6 Interviews For This Weeks’ 199th TV Broadcast, Sunday, July 18, 2021, Hour Slot 10-11 AM ET
New To The Street / Newsmax TV Announces 6 Interviews For This Weeks’ 199th TV Broadcast, Sunday, July 18, 2021, Hour Slot 10-11 AM ET.
About this update from Winners Inc
[{"type":"text","content":"\n NEW YORK, July 16, 2021 (GLOBE NEWSWIRE) -- FMW Media’s New to The Street / Newsmax TV announces its TV airing of this weeks’, Sunday, July 18, 2021, broadcasting line-up of its national syndicated 1- hour show, 10-11AM ET. New to The Street’s 199th production of its TV show features 6 interviews of the following Companies and their businesses representatives: 1). Rritual Superfoods, Inc. (OTCQB:RRSFF) interview with David Kerbel, CEO 2). AzurRx BioPharma, Inc.’s (NASDAQ:AZRX) interview with James Sapirstein, Chairman & CEO 3). Golden Triangle Ventures, Inc.’s (OTCPink:GTVH) interview with Steffan Dalsgaard, CEO 4). GlobeX Data Ltd’s. (OTCQB:SWISF) (CSE:SWIS) (FRA:GDT) interview with Mr. Alain Ghiai, CEO 5). Black Bird Biontech, Inc.’s (OTCPink:BBBT) interview with Fabian G. Deneault, President 6). Winners Inc.’s (OTCPink:WNRS) interview with Mr. Wayne Allyn Root, CEO During the show, watch for the special segment, featuring Mr. Alain Ghaia, internet privacy expert, talking about Sekur®, (a division of GlobeXData); interview with Anna Berry. This week welcomes, on New to The Street TV, David Kerbel, CEO of Rritual Superfoods, Inc. (OTCQB: RRSFF), who provides views with information about the Company’s superfoods and their unique health benefits. He introduces to the audience his wellness brands, Lion's Mane Focus, Reishi Relax, and Chaga Immune. Mr. James Spairstein, Chairman & CEO of AzuRx BioPharma (NASDAQ:AZRX), back again on the show, talking about AZRX’s biopharmaceutical products and therapies. He gives an updated and comprehensive overview in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. And, he provides an update on AZRX’s FDA Phase 2 clinical trials on its lead therapeutic candidate, MS1819 - a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis. New To The Street provides Mr. Steffan Delsgaard, CEO at Golden Triangle Ventures, Inc., (OTCPink:GTVH) the opportunity to talk to viewers about their Company’s operational fundamentals and its successful divisions in health care products / service, nutritional / homeopathic products, California wines, agricultural technologies, and entertainment. Fur...